Peptides News and Research

RSS

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

La Jolla Institute researchers advance work toward vaccine for heart disease

Research toward the world's first vaccine for heart disease continues to advance at the La Jolla Institute for Allergy and Immunology, with researchers demonstrating significant arterial plaque reduction in concept testing in mice.

18 Jun 2014

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

Protein Metrics releases freeware version of Preview software for pre-search protein analysis

Protein Metrics, Inc., a leading provider of software for rapid and thorough protein and peptide characterization, today announced the release of a freeware version of their Preview™ software for pre-search protein analysis available for download from the company's website.

16 Jun 2014

AB SCIEX introduces TripleTOF 6600 system with SWATH Acquisition 2.0

AB SCIEX, a global leader in life science analytical technologies, today introduced the TripleTOF® 6600 system with SWATH™ Acquisition 2.0 - the company's revolutionary solution for quantitative proteomics.

16 Jun 2014

Novel bone implants can keep germs at bay

Hospital germs can be fatal, since they are resistant to antibiotics. As a result, alternative methods of defense against bacteria are in demand. Fortunately, a German-French research team has been able to develop bone implants that keep the germs at bay.

11 Jun 2014

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

Protein Metrics, Inc., a leading provider of software for rapid and thorough protein and peptide characterization, today announced the introduction of top-down analysis as part of the 2.0 release of its Byonic™ proteomics search engine.

11 Jun 2014

Combined chemo and radionuclide therapy stops neuroendocrine tumors

Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Scientists design nanoparticle to target tumor cells

Scientists at UC Santa Barbara have designed a nanoparticle that has a couple of unique - and important - properties.

9 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Device used in physics and chemistry reveals dynamics of pervasive pathogen

If you have it, you probably don't know it. Cytomegalovirus, or CMV, is perhaps one of the biggest pathogens you've never heard of-big, both proportionately and epidemiologically.

6 Jun 2014

Novel technology to block human infections receives I-Corps grant

A novel technology developed at Worcester Polytechnic Institute (WPI) to block human infections by taking a lesson from fish has landed a $50,000 grant from the National Science Foundation's Innovation Corps (I-Corps) program.

5 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat.

4 Jun 2014

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities.

3 Jun 2014

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

Peptides News and Research

New treatment for ovarian cancer can improve response rates

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

La Jolla Institute researchers advance work toward vaccine for heart disease

New approach promises better drugs for diabetes and osteoporosis

Protein Metrics releases freeware version of Preview software for pre-search protein analysis

AB SCIEX introduces TripleTOF 6600 system with SWATH Acquisition 2.0

Novel bone implants can keep germs at bay

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

Combined chemo and radionuclide therapy stops neuroendocrine tumors

Scientists design nanoparticle to target tumor cells

Cardiac biomarkers aid microvascular risk prediction in diabetics

Device used in physics and chemistry reveals dynamics of pervasive pathogen

Novel technology to block human infections receives I-Corps grant

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

AMRI agrees to acquire OsoBio for $110 million

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News